Amryt Pharma PLC (NASDAQ:AMYT; LON:AMYT) said it has signed multi-regional distribution agreements with a company called Medison Pharma.
Medison will sell Amryt’s Juxtapid product in Canada and Lojuxta and Myalept in Israel.
In a statement, Amryt chief executive, Dr Joe Wiley, said: “Today’s announcement is another positive development as we continue to grow our commercial assets in existing and new territories and we further progress towards our goal of becoming a global leader in rare and orphan diseases."
“We are excited to be working with Medison to leverage their expertise and presence in these territories,” he added.
Amryt specialises in treating rare diseases.